Michael McCaughan
Add Sepracor Inc.’s beta-agonist levalbuterol (Xopenex) to the growing list of new formulations or chemical derivatives hit by adverse coverage decisions issued by the Centers for Medicare & Medicaid Services.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?